Patient-Centered Hormone Optimization Precision Therapy

Patient-Centered Hormone Optimization and Recovery

Abstract

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I present a comprehensive, first-person educational post that walks you through how I design, deliver, and monitor integrative hormone optimization across key life stages—postpartum, menopause, and male hypogonadism—and how I execute hormone pellet therapy with procedural precision. I explain how I time labs and follow-ups to align with endocrine physiology; why I prioritize free hormone fractions over total measures; how I use symptom checklists for shared decision-making; and how I integrate chiropractic biomechanics, autonomic regulation, sleep optimization, and targeted nutrition to amplify endocrine outcomes. I detail sterile field setup, deep-plane trocar technique, pellet distribution for stable pharmacokinetics, scar minimization, and complication prevention. The goal is a clear, practical roadmap that merges biomedical precision with biomechanical and behavioral care so patients improve faster and stay better longer.

Why Timing Is Therapy: The Physiology-First Cadence I Use

When I plan endocrine care, I start by aligning my assessments with the body’s clocks. Hormones act on multiple time scales—some non-genomic effects occur within minutes, while genomic programming takes weeks. Matching my timing to those realities increases accuracy and reduces therapeutic inertia.

• Acute checkpoints: For interventions with rapid effects, I sometimes gather an early datapoint—such as a targeted assessment approximately 45 minutes after administration—when pharmacodynamics predict a meaningful response. This helps me connect pharmacokinetics to symptom shifts and adjust dose or route precisely (Rowland & Tozer, 2012).
• Early course correction: If patients remain symptomatic despite a planned short intervention, I do not wait two to three months. I recheck targeted labs within 5–8 days to confirm directional change. This reduces the risk of drifting on an ineffective path.
• Programmed follow-ups: I typically schedule a structured assessment at about 14 weeks for women and 18 weeks for men, the windows where tissue-level adaptations stabilize and symptoms “catch up” to biochemical changes.

Why this approach works: Steroid receptors generate rapid non-genomic actions and slower transcriptional effects; thyroid signaling likewise spans rapid mitochondrial influences and slower nuclear effects. By staging labs and visits across these time scales, I capture both the quick wins and the deeper resets (Lösel & Wehling, 2003; Fuentes & Silveyra, 2019).

Citations:

• Rowland, M., & Tozer, T. N. (2012). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications.
• Lösel, R., & Wehling, M. (2003). Nongenomic actions of steroid hormones.
• Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms.

Building a Data-Rich Profile: The Required Details That Guide Dosing

My algorithms are only as good as the inputs. I require specific intake fields because they shape both safety and effectiveness.

• Birth year and vascular age: Cardiometabolic context moderates hormone benefits and risks.
• Diagnosis and symptom chronology: Duration of estrogen deprivation affects receptor sensitivity and titration safety; long-standing hypoestrogenism calls for a slower start (Manson et al., 2013).
• Current endocrine status: Menstrual cessation, lactation, androgen use, and thyroid status alter SHBG and free hormone availability.
• Past tolerance and side effects: Acne, hair changes, migraines, fluid shifts, guide route, and dosing.
• Activity and body composition: Adiposity raises aromatase activity; lean mass and training change tissue demand and clearance (Macdonald et al., 2023).
• Comorbidities and medications: SSRIs, statins, glucocorticoids, and thyroid agents influence hepatic clearance, transport proteins, and receptor crosstalk (Stuenkel et al., 2015).

Citations:

• Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes.
• Macdonald, T. L., et al. (2023). Body composition and sex steroid metabolism in midlife.
• Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause.

Postpartum Precision: Judicious “Boosts” and Lab-Driven Care

In the immediate postpartum window, physiology is in flux. I sometimes use a one-time, carefully calculated dose after initial labs confirm a pattern that explains symptoms. This “probe” dose is not standing therapy; it is a bridge that informs the next step.

• Why: Estrogen and progesterone plummet after placental delivery; prolactin rises with lactation; thyroid autoimmunity can flare as immune tolerance recedes. A conservative, data-guided probe lets me evaluate symptom response without overtreating during a fragile reset (Gronowski & Fantz, 2020; Gordon et al., 2017).
• Physiology:
  • HPO axis: Low estrogen lowers GABAergic tone, destabilizing sleep and mood.
  • HPT axis: Postpartum thyroiditis risk rises; fluctuations can mimic depression and fatigue.
  • HPA axis: Sleep disruption increases cortisol variability and insulin resistance.

Citations:

• Gronowski, A. M., & Fantz, C. R. (2020). Clinical laboratory testing in pregnancy.
• Gordon, A., et al. (2017). Postpartum depression: Evidence-based treatment.

Menopause and the Timing Hypothesis: Start Low, Go Slow

I respect the “timing hypothesis”: earlier hormone therapy initiation, closer to the final menstrual period, may offer greater benefit with less risk than starting many years later, particularly for vascular outcomes (Manson et al., 2013).

• Endothelium: Estradiol supports nitric oxide availability and repair; late initiation in a fibrotic plaque environment warrants cautious titration.
• Neuroendocrine adaptation: Prolonged deprivation alters receptor density and neurotransmitter homeostasis; a conservative start reduces mastalgia, migraines, or mood swings.
• Hepatic handling: Age and metabolism shift SHBG and clotting factor responses; I often prefer transdermal estradiol to reduce thrombotic risk relative to oral routes (L’Hermite, 2017).

Citations:

• Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes.
• L’Hermite, M. (2017). Transdermal estradiol safety.

Advanced Lab Strategy: Free vs Total Hormones, SHBG, and Context

I measure what matters to tissues. Free hormone fractions and SHBG levels often determine how patients feel, even when total hormone levels appear “normal.”

• Thyroid evaluation: TSH, free T4, free T3, anti-TPO/anti-Tg, sometimes reverse T3 when conversion issues are suspected—plus ferritin, B12, selenium, iodine status, and CRP (Chaker et al., 2017).
• Sex hormone strategy (men): Total T plus free T (equilibrium dialysis preferred or calculated with SHBG and albumin), SHBG, LH/FSH, DHEA-S, sensitive estradiol, hematocrit, lipids, PSA when indicated, A1C, CRP.
• Sex hormone strategy (postmenopause): Estradiol, progesterone, FSH/LH, DHEA-S, thyroid, and cardiometabolic markers.
• Why free fractions: Free testosterone drives receptor binding. Low free T with “normal” total T can explain persistent symptoms (Antonio et al., 2016). Low SHBG levels signal hepatic insulin resistance and shift free hormone exposure (Lima et al., 2012).

Citations:

• Chaker, L., et al. (2017). Hypothyroidism.
• Antonio, J., et al. (2016). Low free testosterone and symptoms.
• Lima, N., et al. (2012). Low SHBG and metabolic syndrome.

Symptom Checklists: Validating Care and Guiding Titration

I use structured individual symptom checklists to complement labs—not replace them.

• Baseline burden: Mood, energy, libido, cognition, sleep, somatic symptoms.
• Trajectory tracking: Symptom score improvements corroborate biochemical gains and ground shared decision making.
• Documentation: Pre- and post-trajectories provide defensible records and clarity.

Why this matters: Perceived well-being can precede or lag behind hormonal changes due to receptor sensitivity and the neural integration of interoceptive signals. Tracking both lenses captures the full picture (Kissler et al., 2019).

Citation:

• Kissler, J. L., et al. (2019). Neurobiology of interoception and mood.

Integrative Chiropractic Care: Modulating Autonomics and Metabolic Biology

As a chiropractor and nurse practitioner, I integrate biomechanics, autonomic regulation, and exercise physiology to amplify endocrine therapy.

• Why it helps:
  • Pain and dyskinesis amplify sympathetic tone and cortisol, destabilizing insulin sensitivity and sex hormone balance (McEwen, 2007).
  • Autonomic dysregulation blunts vagal tone and sleep, blocking hormone efficacy (Thayer & Lane, 2009).
  • Mechanical pain reduces activity, thereby decreasing beneficial myokines and worsening insulin resistance (Pedersen & Febbraio, 2012).
• Clinical techniques:
  • High-velocity, low-amplitude adjustments are indicated when necessary to normalize segmental motion.
  • Graded mobility, soft-tissue release, and respiratory-vagal drills (e.g., 4-7-8 breathing).
  • Progressive resistance training aligned to joint tolerance and hormone status.
• Outcome rationale:
  • Lower allostatic load improves HPA-axis signaling, CRP, and receptor sensitivity.
  • Better mechanics enable higher-intensity training that enhances glucose uptake and reshapes adiposity.

Citations:

• McEwen, B. S. (2007). Physiology and neurobiology of stress.
• Thayer, J. F., & Lane, R. D. (2009). HRV, stress, and health.
• Pedersen, B. K., & Febbraio, M. A. (2012). Muscle as a secretory organ.

Case Narrative: A 59-Year-Old Postmenopausal Woman

A decade postmenopausal, she reports mental fatigue, low libido, mood changes, bladder symptoms, and constipation with gas/bloating.

• Thyroid axis: TSH ? 20.8 mIU/L, low free T4 and low-end free T3, positive TPO antibodies. The diagnosis is primary hypothyroidism with autoimmunity and impaired conversion. I treat with levothyroxine or T4/T3 combination where appropriate and address autoimmune drivers with selenium (?200 mcg/day), myo-inositol, vitamin D optimization, and gut modulation (Jonklaas et al., 2014; Esposito et al., 2016).
• Micronutrients: Ensure robust B12 (>800 pg/mL when clinically indicated), evaluate ferritin (avoid both deficiency and overload), and optimize vitamin D3 with K2 (MK-7) for bone-vascular synergy (Karpinski et al., 2022).
• Estrogen-progestogen: If no contraindications, consider low-dose transdermal estradiol with micronized progesterone to address urogenital, vasomotor, mood, and bone outcomes, aligning with The North American Menopause Society guidance.
• Gut-directed care: Motility support (magnesium citrate/glycinate), fiber periodization, probiotics, possible prokinetics, and short, structured low-FODMAP trials to reduce fermentative load and systemic cytokines.
• Chiropractic fit: Lumbopelvic adjustments, sacral mobilization, and pelvic floor-diaphragm coordination can improve bowel rhythm and reduce pelvic pressure, which enhances adherence.

Citations:

• Jonklaas, J., et al. (2014). ATA guidelines for hypothyroidism.
• Esposito, D., et al. (2016). Selenium and myo-inositol in thyroid support.
• Karpinski, M., et al. (2022). Vitamin K2 in bone and cardiovascular health.
• The North American Menopause Society. (2022). 2022 hormone therapy position statement.

Case Narrative: A 59-Year-Old Man With Low Drive and Metabolic Strain

He reports low energy, decreased motivation, and reduced physical activity with twice-weekly exercise.

• Androgens: Total testosterone ? 300 ng/dL, but free T ? 7.0 is very low. SHBG is very low, signaling hepatic insulin resistance. This pattern is consistent with symptomatic hypogonadism despite a “normal” total (Antonio et al., 2016; Lima et al., 2012).
• Metabolic overlay: Elevated A1C, CRP, and lipids improve as visceral adiposity declines. Testosterone repletion, where indicated, plus progressive resistance training raises insulin sensitivity and lean mass (Grossmann & Matsumoto, 2017).
• Dosing strategy: I titrate conservatively, track free fractions, and watch hematocrit, lipids, estradiol, and PSA when age-appropriate. More active patients often require individualized dosing due to perfusion and receptor demand (Coviello et al., 2008).
• Chiropractic fit: Thoracic extension drills, hip capsule mobility, core activation, and autonomic recalibration improve sleep and growth hormone pulses, supporting recovery and metabolic change.

Citations:

• Antonio, J., et al. (2016). Free vs total testosterone and symptoms.
• Lima, N., et al. (2012). SHBG and metabolic syndrome.
• Grossmann, M., & Matsumoto, A. M. (2017). Holistic management in functional hypogonadism.
• Coviello, A. D., et al. (2008). T kinetics with hCG context.

Pellet Therapy Done Right: Technique, Tissue Planes, and Pharmacokinetics

When I perform hormone pellet implantations, small procedural details can make a large difference in comfort, consistency, and outcomes.

• Follow-up cadence: I check in at 4–5 weeks, then again about a week later, and I schedule program visits at roughly 14 weeks for women and 18 weeks for men, adapting to individual response.
• Why depth and plane matter:
  • Too superficial increases extrusion, microhematoma, and erratic release.
  • I target the deep subcutaneous plane—below superficial fascia, above muscle—where shear is lower, and diffusion is steadier (Kruglikov & Scherer, 2016).
  • I gently fan or distribute pellets along a linear track to increase the interfacial area, thereby stabilizing release curves and reducing local irritation (Siepmann & Siepmann, 2012).
• Clean-to-sterile workflow: I set a meticulous field, make a small incision aligned with Langer’s lines, and use a two-piece trocar with a conical tip for dilation rather than cutting, limiting trauma and hematoma formation (Mustoe et al., 2002; Chudnoff et al., 2016).
• Closure and compression: Precise Steri-Strip apposition, light adhesive support around but not across the fresh wound, and a T-shaped compression dressing minimize dead space, bruising, and scar width.
• Post-procedure instructions: Keep Steri-Strips in place for 5 days, avoid hot tubs and heavy sweating for 5 to 7 days, and limit shear-producing movements. Early rest supports the fibrin scaffold and angiogenesis, leading to robust healing (Gurtner et al., 2008).

Citations:

• Kruglikov, I. L., & Scherer, P. E. (2016). Adipose and fascia in skin.
• Siepmann, J., & Siepmann, F. (2012). Diffusion-controlled drug delivery.
• Mustoe, T. A., et al. (2002). Scar minimization recommendations.
• Chudnoff, S., et al. (2016). Subdermal insertion tool designs.
• Gurtner, G. C., et al. (2008). Wound healing mechanisms.

Regulatory Clarity and Route Trade-Offs: Pellets, Transdermals, Injections

Patients ask whether pellets are “FDA approved.” I provide precise education and documented consent.

• Regulatory nuance: The pellet procedure itself is not FDA-approved. However, ingredients can be FDA-approved and produced in FDA-inspected facilities. Compounding can occur under 503A (state oversight) or 503B (FDA oversight) standards (FDA, 2023).
• Route decisions:
  • Pellets: Excellent adherence and steady-state kinetics; less reversible if dose overshoots.
  • Transdermals: Lower thrombotic signal than many oral estrogens due to bypassing first-pass hepatic effects (L’Hermite, 2017).
  • Injections: Flexible titration; monitor peak–trough variability and aromatization, especially with higher adiposity.

Citations:

• U.S. Food & Drug Administration. (2023). Compounding and FDA oversight.
• U.S. Food & Drug Administration. (2023). Understanding off-label use.
• L’Hermite, M. (2017). Transdermal estradiol safety.

Safety, Monitoring, and Lab Timing: Avoiding Noise and Overreaction

I draw a balance between data sufficiency and over-testing.

• Cadence:
  • Baseline before initiating therapy.
  • Early follow-up once steady state is achieved (often 6–12 weeks, depending on the route).
  • Then, annual labs, unless symptoms dictate earlier checks.
• Men on testosterone: Monitor hematocrit, lipids, liver enzymes, estradiol, and PSA when indicated. Address sleep apnea, dehydration, and interval/route before reflexively stopping therapy if erythrocytosis emerges (Bhasin et al., 2018).
• Women on hormones: Use the lowest effective dose, reassess risk regularly, and individualize the dosing interval as pharmacokinetics and symptom duration evolve.

Citations:

• Bhasin, S., et al. (2018). Endocrine Society guideline on testosterone therapy.
• The North American Menopause Society. (2022). 2022 hormone therapy position statement.

Foundational Co-Therapies: Vitamin D, K2, Omega-3s, Magnesium, and Metabolic Aids

I treat nutraceuticals as true prescriptions—with clear indications, dosages, and reassessment plans.

• Vitamin D3 with K2: I often target 25(OH)D between 30–50 ng/mL and pair with K2 (MK-7) for bone-vascular synergy (Bouillon et al., 2019; Karpinski et al., 2022).
• Omega-3s: Reduce triglycerides and inflammatory mediators, support endothelial function (Calder, 2015).
• Magnesium: Improves sleep, glycemic control, and supports hundreds of enzymatic reactions critical for endocrine resilience.
• Inositol and berberine: Useful for insulin resistance and androgen excess phenotypes when clinically indicated; I monitor GI tolerance and potential interactions.

Citations:

• Bouillon, R., et al. (2019). Vitamin D and human health.
• Karpinski, M., et al. (2022). Vitamin K2 in bone and cardiovascular health.
• Calder, P. C. (2015). Omega-3 fatty acids and inflammation.

Digital-First Patient Education: QR Videos, PDFs, and Spaced Cues

Patients forget details after visits. To close the gap, I deliver 4×6 QR-coded cards linking to short videos and provide downloadable PDFs that repeat post-procedure steps, supplement timing, activity restrictions, and red-flag symptoms.

• Spaced learning: Videos arrive immediately post-visit, at three weeks, and again near key milestones to prompt booking and adherence. This spaced cueing consolidates memory and reduces inbound call volume (Aguinis et al., 2012).
• Telemedicine integration: I combine remote consults with transparent, cash-based follow-ups to reduce barriers for families and professionals.

Citation:

• Aguinis, H., et al. (2012). RCTs to evaluate training programs.

Inventory Control and Audit-Ready Workflows for Controlled Therapies

For therapies such as testosterone, I maintain rigorous inventory control.

• Daily reconciliation: Every tablet or implant, lot number, and dose is logged and matched to dispensing.
• Digital platforms: I use systems that automatically capture lot and dispensing details, reducing manual errors.
• Audit readiness: Documentation and physical counts must match; daily reconciliation keeps the ledger clean.

This protects patients, staff, and access to care.

Practical Pearls From My Clinic

Drawing from my daily practice and updates I share on chiropracticscientist.com and LinkedIn:

• Patients with combined thyroid autoimmunity and gut dysbiosis often improve fastest when we synchronize thyroid therapy, gut-directed care, and autonomic recalibration. This triple synergy restores stable energy and cognitive clarity within weeks.
• Men with low free testosterone and low SHBG turn the corner when we implement posterior-chain strength, thoracic mobility, and carefully titrated androgens. CRP and A1C often fall alongside waist size, even before the scale shifts dramatically.
• In pellet care, adjusting depth, angle, and distribution reduced post-procedure soreness and “rollercoaster” weeks, boosting adherence and long-term satisfaction.
• Video education and pre-scheduled follow-ups consistently improve engagement and lab outcomes at 14–18 weeks.

Putting It All Together: A Cohesive Integrative Care Model

• Assessment: Comprehensive history; required intake fields; symptom checklists; problem-focused labs.
• Education: White paper-style informed consent; route-specific risks and benefits; clear post-procedure instructions.
• Intervention: Conservative, algorithmic titration aimed at restoring physiologic free hormone ranges; route choice matched to physiology and preference.
• Integrative chiropractic care: Spinal/musculoskeletal alignment, mobility restoration, autonomic balance to reduce HPA burden and improve sleep and training response.
• Lifestyle prescriptions: Nutrition, resistance training, and sleep programming as co-therapies with clear dosing analogs.
• Monitoring: Staged labs at steady state, then annually; symptom-driven check-ins; safety markers appropriate to therapy.
• Documentation: Signed plans and instruction sheets were retained and provided to patients; inventory control aligned with regulatory expectations.

The synthesis of biomedical precision, biomechanical optimization, and behavioral consistency is what makes integrative hormone care truly effective and sustainable.

References

• Aguinis, H., Gottfredson, R. K., & Joo, H. (2012). Using randomized controlled trials to evaluate training programs: A primer. Annual Review of Organizational Psychology and Organizational Behavior, 1(1), 47–73.
• Antonio, J., Wilson, J., & Wilson, G. J. (2016). Low free testosterone in the presence of normal total testosterone in males: What does it mean? Physiology & Behavior, 164, 345–350.
• Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Wu, F. C. W. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
• Bouillon, R., Marcocci, C., Carmeliet, G., et al. (2019). Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocrine Reviews, 40(4), 975–1017.
• Calder, P. C. (2015). Omega-3 polyunsaturated fatty acids and inflammatory processes. Nutrients, 7(4), 273–289.
• Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550–1562.
• Chudnoff, S., et al. (2016). Device design and complication profiles for subdermal insertion tools. Obstetrics & Gynecology Devices Review.
• Coviello, A. D., et al. (2008). Low-dose hCG maintains intratesticular testosterone in men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology & Metabolism, 90(5), 2595–2602.
• Esposito, D., et al. (2016). The role of selenium and myo-inositol in the treatment of subclinical hypothyroidism. International Journal of Endocrinology, 2016, 1–9.
• Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in Protein Chemistry and Structural Biology, 116, 135–170.
• Gurtner, G. C., et al. (2008). Wound healing: A review. The New England Journal of Medicine, 359, 1037–1046.
• Gronowski, A. M., & Fantz, C. R. (2020). Clinical laboratory testing in pregnancy. Clinical Chemistry, 66(1), 149–159.
• Grossmann, M., & Matsumoto, A. M. (2017). A perspective on middle-aged and older men with functional hypogonadism. Journal of Clinical Endocrinology & Metabolism, 102(3), 1067–1075.
• Jonklaas, J., et al. (2014). Guidelines for the treatment of hypothyroidism: ATA Task Force. Thyroid, 24(12), 1670–1751.
• Kissler, J. L., et al. (2019). Neurobiology of interoception and mood. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 4(3), 262–271.
• Karpinski, M., et al. (2022). Vitamin K2 in bone and cardiovascular health. Nutrients, 14(1), 174.
• Kruglikov, I. L., & Scherer, P. E. (2016). The role of adipocytes and adipocyte-like cells in the skin. Experimental Dermatology, 25(2), 92–99.
• L’Hermite, M. (2017). Risks and benefits of hormone therapy: The role of transdermal estradiol and micronized progesterone. Drugs & Aging, 34(8), 555–564.
• Lima, N., Cavaliere, H., Knobel, M., Halpern, A., & Medeiros-Neto, G. (2012). Low SHBG: A strong association with metabolic syndrome. Arquivos Brasileiros de Endocrinologia & Metabologia, 56(1), 9–15.
• Lösel, R., & Wehling, M. (2003). Nongenomic actions of steroid hormones. Nature Reviews Molecular Cell Biology, 4, 46–56.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during and after WHI trials. The New England Journal of Medicine, 368(17), 1681–1692.
• McEwen, B. S. (2007). Physiology and neurobiology of stress. Physiological Reviews, 87(3), 873–904.
• Mustoe, T. A., Cooter, R. D., Gold, M. H., et al. (2002). International clinical recommendations on scar management. Plastic and Reconstructive Surgery, 110(2), 560–571.
• Pedersen, B. K., & Febbraio, M. A. (2012). Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nature Reviews Endocrinology, 8, 457–465.
• Rowland, M., & Tozer, T. N. (2012). Clinical pharmacokinetics and pharmacodynamics. Lippincott Williams & Wilkins.
• Siepmann, J., & Siepmann, F. (2012). Modeling of diffusion controlled drug delivery. Journal of Controlled Release, 161(2), 351–362.
• Stuenkel, C. A., Davis, S. R., Gompel, A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011.
• The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.
• Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart-brain axis. International Journal of Psychophysiology, 73(2), 73–80.
• U.S. Food & Drug Administration. (2023). Compounding and FDA oversight of human drugs.
• U.S. Food & Drug Administration. (2023). Understanding unapproved use (off-label) of approved drugs.